Rocket Pharmaceuticals announced on Tuesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) regarding a trial for its cutting-edge treatment for Danon disease. This significant milestone paves the way for the company’s study, which will evaluate key endpoints after a 12-month period. Successful results from this trial will potentially enable the FDA to grant accelerated approval for the treatment. Following this exciting news, Rocket Pharmaceuticals experienced a considerable surge, with shares rising by an impressive 27% to reach $19.40 after-hours.
KULR Technology Group Plans Underwritten Public Offering of Common Stock
KULR Technology Group, a prominent sustainable energy management company, recently announced its plans to initiate an underwritten public offering of common stock. The primary purpose of this offering is to pay off an outstanding balance owed under a credit facility. Moreover, KULR Technology Group intends to utilize the proceeds for general corporate purposes and working capital, further strengthening its operations. However, this announcement had a downside impact on the company’s stock price, causing shares to drop by 23% to 45 cents after-hours, landing below their 52-week low.
Evolution Petroleum Reports Sharp Revenue Decline in Fiscal Fourth Quarter
Evolution Petroleum, a leading player in the energy sector, recently disclosed a considerable drop in revenue for the fiscal fourth quarter. This decline can be attributed to lower volumes of oil and natural gas sold at reduced realized prices. As a result, the company’s earnings per share ended up breaking even. Consequently, Evolution Petroleum experienced a decline in its stock price, with shares falling by 13% to $7.72.
